Adams’ Suit Could Delay ANDA For URL/Mutual’s Mucinex Generic
This article was originally published in The Tan Sheet
Executive Summary
A lawsuit filed by Adams Respiratory Therapeutics could bring a stay of up to 30 months on FDA's approval of Mutual Pharmaceuticals and United Research Laboratories' application for a generic version of Adams' Mucinex extended-release expectorant product
You may also be interested in...
Adams Reinforces Mucinex Patents In Settlement Agreement With Mutual
A settlement agreement granting United Research Labs/Mutual Pharmaceuticals a conditional license for certain guaifenesin products could help Adams Respiratory Therapeutics fend off other potential generic competition for its Mucinex brand
FTC Clarification Of Law On Citizen Petitions Could Bring Antitrust Scrutiny
The Federal Trade Commission wants to clarify through case law that repeated petitioning of the government could bring antitrust enforcement, even if petitioners make scientific and regulatory arguments
Adams To File Citizen Petition In Move To Block Generic Mucinex
Adams Respiratory Therapeutics is planning to file a citizen petition in an attempt to fend off generic competition against its 600 mg and 1200 mg Mucinex product (extended-release guaifenesin)